Physician

Samuel Jacob Slomowitz, M.D.

According to 2025 Medicare claims, Samuel Slomowitz, M.D. (NPI: 1659525756) practices hematology/oncology in the Oxnard-Thousand Oaks-Ventura, CA market, with the plurality of this provider's patient population coming from Ventura, CA. This provider's primary affiliated billing organization is THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1235107566; TIN: 954373071) and primary practice location at 91361-3705.

Slomowitz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 863 traditional Medicare patients, billed 330,600 HCPCS/CPT codes, and received $5,412,629 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 770 prescription claims across 189 beneficiaries totaling $3,514,454 in drug costs, led by Xtandi (Enzalutamide). DME data shows 41 claims. Open Payments data shows 1 records totaling $38. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $654,697 to $5,412,629. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $667,147 to $3,514,454. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,905 and ending at $1,280.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	347	76,763	$654,697
2016	444	125,238	$1,241,146
2017	450	148,890	$1,790,789
2018	663	196,213	$2,818,216
2019	815	352,928	$5,594,917
2020	792	419,043	$5,148,273
2021	838	450,501	$5,738,668
2022	810	360,645	$5,158,752
2023	903	373,509	$5,148,568
2024	863	330,600	$5,412,629

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	111	700	$667,147
2016	152	1,017	$1,181,111
2017	186	1,287	$1,324,753
2018	230	1,396	$2,206,050
2019	285	2,034	$3,930,037
2020	272	1,813	$3,998,035
2021	240	1,435	$4,864,123
2022	216	1,208	$5,661,872
2023	218	932	$3,892,310
2024	189	770	$3,514,454

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	25	74	$28,459
2017	N/R	57	$14,153
2018	11	127	$12,648
2019	N/R	145	$15,803
2020	11	156	$9,118
2021	11	153	$9,402
2022	N/R	79	$2,856
2023	N/R	35	$7,458
2024	N/R	41	$993

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	127	678	$115
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	606	2,551	$103
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	522	1,230	$13
36415	Insertion of needle into vein for collection of blood sample	120	338	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	466	2,153	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	40	1,200	$572,767
Kisqali	Ribociclib Succinate	25	700	$379,478
Xpovio	Selinexor	12	336	$281,547
Imbruvica	Ibrutinib	12	336	$267,100
Jakafi	Ruxolitinib Phosphate	13	390	$224,475

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	23	$673
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$320

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$38	INTUITIVE SURGICAL, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Samuel Jacob Slomowitz, M.D.?

Tedicare shows public-source Medicare data for Samuel Jacob Slomowitz, M.D. (NPI 1659525756), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Samuel Jacob Slomowitz, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Samuel Jacob Slomowitz, M.D.?

Samuel Jacob Slomowitz, M.D. is linked to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1235107566) in the available physician profile data.

Does Samuel Jacob Slomowitz, M.D. have Open Payments data?

Samuel Jacob Slomowitz, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.